STOCK TITAN

Collegium Pharmaceutical Inc - COLL STOCK NEWS

Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.

About Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.

Core Business and Product Portfolio

At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.

In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.

Technological Innovation: The DETERx® Platform

Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.

Strategic Growth and Market Position

Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.

With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.

Commitment to Responsible Pain Management

Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.

Conclusion

Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.

Rhea-AI Summary

Collegium Pharmaceutical, Inc. announced a $35 million Accelerated Share Repurchase (ASR) program with Jefferies to buy back common stock as part of a $150 million repurchase program. The company aims to enhance shareholder value by leveraging its capital deployment strategy. The ASR agreement will result in Collegium receiving 888,889 shares initially, with the final number based on stock prices during the term.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
buyback
-
Rhea-AI Summary

Collegium Pharmaceutical, Inc. reported strong Q1 2024 financial results, including a net revenue of $144.9 million, record Belbuca® revenue of $50.7 million, and GAAP net income of $27.7 million. The company achieved a 5% increase in Adjusted EBITDA, authorized a $35.0 million share repurchase program, and reaffirmed its full-year 2024 guidance. Collegium also announced an authorized generic agreement with Hikma and a leadership transition. Financially, the company showed stable product revenues, reduced GAAP operating expenses, and increased cash reserves.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.8%
Tags
-
News
Rhea-AI Summary

Collegium Pharmaceutical, Inc. announces CEO transition as Joe Ciaffoni steps down as President and CEO, effective May 24, 2024. Michael Heffernan will serve as Interim President and CEO until a successor is appointed. The Board has initiated the search for a new CEO. Collegium remains financially strong and on track to achieve its 2024 financial guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.8%
Tags
none
Rhea-AI Summary

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will report its first quarter 2024 financial results on May 9, 2024, after the market closes. The company aims to improve the lives of individuals with severe medical conditions. A live conference call and webcast will follow the financial report at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences earnings
-
Rhea-AI Summary
Collegium Pharmaceutical, Inc. announces the redemption of $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026, with a redemption price of approximately $1,008.68 per $1,000 principal amount of Notes. The redemption is triggered by the last reported sale price of the Company's Common Stock exceeding 130% of the conversion price of the Notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (COLL) will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on April 10, 2024. The event will be webcast live and accessible from the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences
-
Rhea-AI Summary
Collegium Pharmaceutical, Inc. reported record quarterly and full-year net revenue, achieved GAAP net income, and delivered record adjusted EBITDA. The company ended 2023 with strong financials and cash reserves. Business highlights include growth in prescriptions, share repurchase programs, and contract renegotiations. The company reaffirms its full-year 2024 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA. Financial results for the quarter and year ended December 31, 2023, show significant increases in net revenue, GAAP net income, and adjusted EBITDA compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.79%
Tags
-
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will report Q4 and full-year 2023 financial results on February 22, 2024. A live conference call and webcast will follow. The Company is focused on improving the lives of people with serious medical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences earnings
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) expects product revenues of $580.0 million to $595.0 million, adjusted operating expenses of $120.0 million to $125.0 million, and adjusted EBITDA of $380.0 million to $395.0 million in 2024. The company also authorized a $150.0 million share repurchase program. Collegium's 2023 financial performance was strong, with over 20% revenue growth and over 35% adjusted EBITDA growth compared to 2022. The company returned $75.0 million in capital to shareholders in 2023 and renegotiated major contracts for its products, positioning it for growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.42%
Tags
none

FAQ

What is the current stock price of Collegium Pharmaceutical (COLL)?

The current stock price of Collegium Pharmaceutical (COLL) is $29.39 as of April 1, 2025.

What is the market cap of Collegium Pharmaceutical (COLL)?

The market cap of Collegium Pharmaceutical (COLL) is approximately 937.9M.

What does Collegium Pharmaceutical Inc. specialize in?

Collegium specializes in developing and commercializing abuse-deterrent medications for chronic pain and other serious medical conditions using its proprietary DETERx® technology.

What is the DETERx® technology platform?

DETERx® is Collegium’s proprietary technology that enables the development of extended-release medications resistant to common forms of abuse, such as crushing or dissolving.

What are Collegium’s key products?

Collegium’s key products include Xtampza ER® for chronic pain, the Nucynta® franchise for acute and chronic pain, and Jornay PM® for ADHD treatment.

How does Collegium address opioid misuse and abuse?

Collegium addresses opioid misuse and abuse through its abuse-deterrent formulations, which maintain efficacy while reducing the potential for non-medical use.

What was the significance of the Ironshore Therapeutics acquisition?

The acquisition of Ironshore Therapeutics added Jornay PM®, an ADHD medication, to Collegium’s portfolio, diversifying its offerings and expanding into the neuropsychiatry market.

Where is Collegium Pharmaceutical headquartered?

Collegium Pharmaceutical is headquartered in Stoughton, Massachusetts, USA.

How does Collegium differentiate itself in the pharmaceutical industry?

Collegium differentiates itself through its focus on abuse-deterrent technologies, a diversified product portfolio, and strategic growth initiatives in specialized therapeutic areas.

What markets does Collegium operate in?

Collegium operates in the pain management and neuropsychiatry markets, addressing unmet medical needs with innovative, abuse-deterrent medications.
Collegium Pharmaceutical Inc

Nasdaq:COLL

COLL Rankings

COLL Stock Data

937.93M
31.00M
1.93%
121%
17.19%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
STOUGHTON